IL2 and neoplasm: The immunocytokine (IC) IL-2, i.e., L19-IL2, in which IL-2 was fused to a humanized mAb L19, was capable of specific accumulation in tumor neovasculature, showing encouraging results in patients with metastatic melanoma [78].